NERV — Minerva Neurosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1598646 ·
Last close
$3.40
Market Cap
$162.34M
52W High
$12.46
52W Low
$2.06
ADV30
238,837
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -10,642,159 | 17,466,285 | 95,088,945 | 24,652,086 | 308,389,568 |
| Mar 2026 | 0 | — | -16,671,552 | -125,404,384 | 94,027,156 | 32,659,770 | 348,041,016 |
| Dec 2025 | 0 | — | -4,981,589 | -283,667,663 | 97,968,888 | 82,301,813 | 238,716,970 |
| Sep 2025 | 0 | — | -2,844,348 | -2,743,954 | 28,092,052 | 12,286,646 | 62,672,322 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-14,866,040
Investing CF
$-45,294,104
Financing CF
$75,575,032
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-29.16
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-814,204,124
Inventory
—
Receivables
—
ST Investments
$45,405,126
EBIT TTM
$-306,341,757
Pretax Income TTM
$-415,074,589
Interest Exp TTM
$0
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -15,102,970 | -293,423,177 | 97,968,888 | 238,716,970 | -140,748,082 | -13,510,936 |
| Dec 2024 | 0 | -21,848,386 | 1,438,865 | 37,143,744 | 62,836,844 | -25,693,100 | -19,550,567 |
| Dec 2023 | 0 | -23,119,576 | -30,005,353 | 56,899,750 | 85,357,240 | -28,457,490 | -14,784,732 |
| Dec 2022 | 0 | -25,231,326 | -32,108,676 | 55,087,233 | 75,111,452 | -20,024,219 | -24,645,143 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.42
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $3.42 · call volume: 0 · put volume: 1
Expected Move to 2026-11-20:
±$2.05
(59.94%) —
implied range
$1.37 –
$5.47
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ADCT | ADC Therapeutics SA | $162.14M | $1.27 | — |
| NBP | NovaBridge Biosciences | $159.59M | $1.38 | — |
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | $158.98M | $4.20 | — |
| OGI | ORGANIGRAM GLOBAL INC. | $158.57M | $1.10 | — |
| TNXP | Tonix Pharmaceuticals Holding Corp. | $169.11M | $9.86 | — |
News headlines (Yahoo Finance, 1h cache)
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences
2026-08-28 12:00 · Yahoo
Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs
2026-06-01 20:05 · Yahoo
All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy
2026-05-20 16:00 · Yahoo
Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-05-20 13:35 · Yahoo
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
2026-05-05 12:00 · Yahoo
Minerva Announces Leadership Transition
2026-04-02 20:05 · Yahoo
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
2026-03-31 20:05 · Yahoo
NRG Fusion Market Competitive Landscape Report 2026 Featuring Zensun (Shanghai) Sci & Tech, Salubris Biotherapeutics, Hummingbird Bioscience, Minerva Neurosciences
2026-04-13 09:08 · Yahoo
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
2026-08-07 11:00 · Yahoo
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
2026-05-18 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.